IDEFIRIX

This brand name is authorized in Austria, Croatia, Estonia, Finland, Ireland, Israel, Italy, Lithuania, Poland, UK.

Active ingredients

The drug IDEFIRIX contains one active pharmaceutical ingredient (API):

1	Imlifidase UNII UVJ7NL8S2P - IMLIFIDASE
	Imlifidase is a cysteine protease derived from the immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that cleaves the heavy chains of all human IgG subclasses but no other immunoglobulins. The cleavage of IgG leads to elimination of Fc-dependent effector functions, including CDC and antibody-dependent cell-mediated cytotoxicity (ADCC). By cleaving all IgG, imlifidase reduces the level of DSA, thus enabling transplantation.
	Read more about Imlifidase

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IDEFIRIX Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA41		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA41

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1826243, 1826254
FI	Lääkealan turvallisuus- ja kehittämiskeskus	084630, 595693
GB	Medicines & Healthcare Products Regulatory Agency	391969, 391970
IL	מִשְׂרַד הַבְּרִיאוּת	9440, 9441
IT	Agenzia del Farmaco	048988012, 048988024
LT	Valstybinė vaistų kontrolės tarnyba	1091050, 1091051
PL	Rejestru Produktów Leczniczych	100441882